Shelley DiCecco, Claire C Davies, Laura Gilchrist, Kim Levenhagen, Marie-Eve Letellier, Amy Rivera, Jan Weiss, Guenter Klose, Linda Hodgkins, Elizabeth Anderson, Andrea Cheville, Keith Moore, Linda Koehler
{"title":"Complete decongestive therapy phase 1: an expert consensus document.","authors":"Shelley DiCecco, Claire C Davies, Laura Gilchrist, Kim Levenhagen, Marie-Eve Letellier, Amy Rivera, Jan Weiss, Guenter Klose, Linda Hodgkins, Elizabeth Anderson, Andrea Cheville, Keith Moore, Linda Koehler","doi":"10.1007/s12032-024-02407-4","DOIUrl":null,"url":null,"abstract":"<p><p>This document was drafted by interdisciplinary experts informed by the evidence and guided by their extensive lymphedema clinical experience at the 2023 American Cancer Society (ACS) Lymphedema Summit: Forward Momentum: Future Steps in Lymphedema Management hosted by the ACS, Lymphology Association of North America, and the Washington School of Medicine in St. Louis, Missouri. Consensus statements were derived from a facilitated workshop and multiple follow-up discussions and meetings combining available evidence and clinical expertise. The consensus statements find that the essential components of complete decongestive therapy (CDT) are examination, compression, manual techniques (this may include but is not limited to manual lymph drainage), exercise, skin care, education, and self-management. Adjunctive interventions and alternatives may complement CDT. CDT should be provided by specifically trained healthcare practitioners in lymphedema management, preferably a certified lymphedema therapist. The individual's lymphedema etiology and presentation, comorbidities, and other pertinent clinical information will determine the components of CDT applied and the frequency and duration of care.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"41 12","pages":"304"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02407-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This document was drafted by interdisciplinary experts informed by the evidence and guided by their extensive lymphedema clinical experience at the 2023 American Cancer Society (ACS) Lymphedema Summit: Forward Momentum: Future Steps in Lymphedema Management hosted by the ACS, Lymphology Association of North America, and the Washington School of Medicine in St. Louis, Missouri. Consensus statements were derived from a facilitated workshop and multiple follow-up discussions and meetings combining available evidence and clinical expertise. The consensus statements find that the essential components of complete decongestive therapy (CDT) are examination, compression, manual techniques (this may include but is not limited to manual lymph drainage), exercise, skin care, education, and self-management. Adjunctive interventions and alternatives may complement CDT. CDT should be provided by specifically trained healthcare practitioners in lymphedema management, preferably a certified lymphedema therapist. The individual's lymphedema etiology and presentation, comorbidities, and other pertinent clinical information will determine the components of CDT applied and the frequency and duration of care.
本文件由跨学科专家在 2023 年美国癌症协会(ACS)淋巴水肿峰会上根据证据和丰富的淋巴水肿临床经验起草而成:前进的动力:会议由美国癌症协会(ACS)、北美淋巴协会(Lymphology Association of North America)和密苏里州圣路易斯华盛顿医学院(Washington School of Medicine)主办。共识声明是在一次研讨会和多次后续讨论和会议上结合现有证据和临床专业知识达成的。共识声明认为,完全缓解充血疗法 (CDT) 的基本组成部分包括检查、加压、手动技术(可能包括但不限于手动淋巴引流)、运动、皮肤护理、教育和自我管理。辅助性干预措施和替代方法可作为 CDT 的补充。CDT 应由受过淋巴水肿管理专门培训的医护人员提供,最好是经过认证的淋巴水肿治疗师。个人的淋巴水肿病因和表现、合并症以及其他相关临床信息将决定 CDT 的应用内容以及护理的频率和持续时间。
期刊介绍:
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.